[Osteoporosis induced by immunosuppressant].
Fukunaga
Jyoji
J
Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine and Dentistry.
Sugahara
Toshio
T
D000818:Animals; D001862:Bone Resorption / Q000139:chemically induced*; D019703:Calcineurin / Q000502:physiology; D065095:Calcineurin Inhibitors; D002352:Carrier Proteins / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D016572:Cyclosporine / Q000009:adverse effects; D016207:Cytokines / Q000378:metabolism; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007371:Interferon-gamma / Q000502:physiology; D008562:Membrane Glycoproteins / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus / Q000009:adverse effects / Q000494:pharmacology
D065095:Calcineurin Inhibitors; D002352:Carrier Proteins; D016207:Cytokines; D006023:Glycoproteins; D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D007371:Interferon-gamma; D016572:Cyclosporine; D019703:Calcineurin; D016559:Tacrolimus